samedan logo
 
 
 
spacer
home > ebr > Winter 2020
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2020

   
Text
PDF
bullet
dna and rna sequencing
The Genetic Revolution

Is Genetic Anonymity Possible?

Dr Tal Sines and Ofer A Lidsky at DNAtix consider the hardly new, but still relevant, notion of a genetic revolution, and what this means in a modern context compared to when the term was first coined.
 
view
download pdf
bullet
Vaccine Controversy
The Future of Vaccination

The Path to a More Effective Influenza Vaccine

Vaccinations play a crucial role in the treatment and, more importantly, prevention of many deadly diseases. However, Dr Scot Roberts at Altimmune argues that there is room for innovation.

 
 
view
download pdf
Vaccination Research

Virus-Like Particles: Versatile Platforms

Vaccine innovation remains an agreed requirement among the pharma industry, and it is in this climate that virus-like particles have gained commendation; David Wetzel at ARTES Biotechnology and Jo-Anne Chan at Burnet Institute discuss.
 
view
download pdf
Diagnostic Reagents in Dengue Vaccine Development

Going Viral

The Native Antigen Company’s Dr Andy Lane discusses life-threatening flaviviruses such as the Dengue virus, and considers the part vaccines have to play in the combat and eventual eradication of these viruses.
 
view
download pdf
bullet
Data Compliance and Misuse
Safeguarding Biopharmaceutical Data

Integrity and Compliance

Data integrity is a critical part of every pharmaceutical company. Thermo Fisher Scientific’s Kimberly Remillard writes on the importance of maintaining integrity, and the possible consequences of data misuse.
 
view
download pdf
Achieving Data Quality in Pharma Traceability Systems

The Elegant Fundamentals

Amit Sewak at rfxcel takes you through the fundamentals of ensuring the accuracy of pharmaceutical data; ranging from respecting the human element to effectively utilising the technology at your disposal.
 
view
download pdf
Q&A: Data Regulations

A Guiding Light

Shweta Nair at Advanced Instruments sits down for an interview with Angela Bazigos, CEO of Touchstone Technologies Silicon Valley and co-author of 21 CFR Part 11 FDA guidelines.
 
view
download pdf
Data Compliance and Integrity

Why is Data Integrity Important?

Laura Grey and Santosh Tymms at Quanticate outline the reasons why data integrity is imperative for every pharmaceutical company and consider how it can best be achieved.
 
view
download pdf
Building Patient Engagement and Secure Drug Discovery

Data Privacy, Compliance, and Security

Much has been made of the trials and tribulations of complying with data regulations; however, Paul Drake at Signant Health argues there may be significant opportunities to be gained from data compliance.


 
view
download pdf
bullet
In Brief
In Brief

Remembering Alzheimer's

EBR’s Industry Advisor, Emile Bellott, considers the growing urgency for a treatment to combat Alzheimer's disease to ensure the quality of life for a population guaranteed to live longer than any previous generation.
 
view
download pdf
bullet
Features
Contract Development and Manufacturing Organisations

The Quality Paradox of Development in a CDMO

Alastair Waugh at 3P Biopharmaceuticals walks us through the challenging role of a contract development and manufacturing organisation and describes the balance of maintaining both work rate throughput and GMP compliance.
 
view
download pdf
Novel Approach for the Early Detection Sepsis

A Viable Solution

Until now, molecular diagnostic technologies for the detection of bacteria in blood have focused solely on the identification of DNA, but ArcisDr Jan Rodgers and Dr Pablo Castan write on a game-changing new bacterial detection technology.
 
view
download pdf
CRISPR-Cas9

Beyond Biopharma

ERS Genomics Trevor Collingwood dives into the ambitions, successes, and future possibilities of CRIPR-Cas9, and the way that it has set itself apart from other platforms.
 
view
download pdf
Q&A: Drug Repurposing for Rare Diseases

Fit for Repurpose

Drug repurposing presents an encouraging possibility for finding cures, especially for rare diseases. EBR sits down with Hermann Mucke from H. M. Pharma Consultancy to deliberate the financial and other implications of drug repurposing for rare diseases.
 
view
download pdf
Generic Competition

Levelling the Playing Field

Charlotte Tillett, Astrid Arnold, and Joe Armstrong at Stevens & Bolton examine the July 2019 manufacturing waiver introduced by the EU and the effects it has and will continue to have on generics and biosimilars.
 
view
download pdf
Flow Monitoring in the Biotech Industry

Supporting Closed Operations with Flexible Single-Use Solutions

Article contributors at SONOTEC delve into single-use solutions and how to utilise noninvasive flow sensors effectively.
 
view
download pdf
Medicinal Cannabis

Why the Regulation of CBD Isn’t ABC

Greer Deal at Global Regulatory Services maps the controversial history of cannabis, the fast-changing regulations for cannabisderived products, and the effect all the aforementioned may have on the market for cannabis-based drugs.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

B Medical Systems launches €15m factory extension in Luxembourg

B Medical Systems (BMS), a global leader in the medical cold chain industry and manufacturer of ultra-low freezers, vaccine refrigerators, freezers, and transport boxes has unveiled a €15m extension at its manufacturing facility in Hosingen, Luxembourg. BMS launched the manufacturing facility in January 2021, which was attended by His Royal Highness Hereditary Grand Duke of Luxembourg, Prince Guillaume.
More info >>

White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement